ADDF has an impressive track record of selecting and supporting excellent AD drug discovery programs.

• As of spring 2009, we have awarded $28.7M for 195 research programs and conferences in 12 countries.

• Our Academic Drug Discovery Program has provided $22.5M to 148 academic international scientists who have created entirely new classes of drugs in development for AD, screened millions of compounds, identified hundreds of new leads, executed many patents and licenses, and are approaching or entering clinical trials with several new drugs.

• We have invested $5.2M in 22 biotechnology companies worldwide. Eleven of them have received follow-on funding commitments of over $325M. Two companies co-founded by ISOA, Allon Therapeutics and Zapaq, have gone on to raise Series A financing. 

• Acumen Pharmaceuticals, a small biotech company that received a $133,493 ISOA grant in January of 2003, succeeded in executing a $48M licensing deal with Merck in February of 2004.

• Of the 128 initial public offerings (IPOs) in biotechnology since 1998, only 9 companies had central nervous system programs and just 5 reported Alzheimer’s disease programs. The only company that had an AD clinical trial at the time of IPO was Corcept Therapeutics and that trial was funded by us.

Despite progress, more needs to be done. Due to limited funds, we can only support about 10% of the programs submitted, leaving much valuable drug discovery research unfunded. We are seeking dedicated partners to help accelerate drug discovery for Alzheimer’s disease. Partner with us to help fund vital research.